At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Deepti H Radia, Guy's and St Thomas' NHS Foundation Trust, London, UK, delivered a presentation on disease biology and molecular architecture in advanced systemic mastocytosis (AdvSM).
In this presentation, Radia discusses the classification and biology of AdvSM, covering mast cell disease biology, the clinical and biological spectrum of AdvSM, KIT as a central molecular driver of AdvSM, additional somatic mutations, clonal architecture and disease evolution, and the mechanisms of disease progression and organ damage.
This educational resource is independently supported by Blueprint medicines. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.